Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d
Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica
Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.
Two of the biggest advances in healthcare in the last decade have been the gradual de-stigmatisation of mental health and the increased interest in researching the causes and treatments of
The latest version of Google DeepMind and Isomorphic Labs’ AlphaFold model can predict the structure and relationships not only of proteins, but “all of life’s molecules”,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.